Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 12,086

Document Document Title
WO/2024/104475A1
Disclosed in the present invention are cyclic compounds used as multi-target kinase inhibitors and a preparation method therefor. The multi-target kinase inhibitors of the present invention are represented by general formula I, wherein R...  
WO/2024/108131A1
The disclosure herein provides compounds and pharmaceutical compositions of Formula (I), (II), (III), (IV), (V), or (VI) for killing cancer cell or inhibiting cancer cell proliferation. Further, the compounds and pharmaceutical compositi...  
WO/2024/108100A1
The present application provides heteroaryl fluoroalkene compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.  
WO/2024/105364A1
The present invention relates to compounds of formula (I). The compounds may be used to inhibit Cdc-Like Kinases, and thereby treat cancer, inflammatory disease, neurodegenerative disease, infection, tendinopathy, Duchenne muscular dystr...  
WO/2024/105070A1
The present invention generally relates to compounds of formula (I) inhibiting the transforming growth factor beta (TGF beta) type I receptor (ALK5) (hereinafter ALK5 inhibitors), methods of preparing such compounds, pharmaceutical compo...  
WO/2024/107686A1
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I' (I') wherein the variables of Formula I' are defined herein. This discl...  
WO/2024/104435A1
Disclosed are a tricyclic PI3Kα inhibitor, a preparation method therefor, and pharmaceutical use thereof. Particularly, the present invention relates to a compound represented by general formula (1), a preparation method therefor, and u...  
WO/2024/104452A1
A compound as shown in formula I, and a racemate, a stereoisomer, a tautomer, an isotopically labeled substance, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, a prodrug, or a pharmaceutically acceptable salt thereof. ...  
WO/2024/105363A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate activity of the HPK-1 protein, and thereby treat cancer, viral infection and immune-mediated disorders.  
WO/2024/102078A1
This invention provides compounds according to formula (I): wherein A and Za are as defined in the specification. The compounds of formula (I) find use as heterobifunctional linkers. The present invention also provides compounds of formu...  
WO/2024/098273A1
An anti-influenza virus phosphate ester compound and a use thereof. The phosphate ester compound is a compound represented by formula (I) below or a hydrate, a solvate, an optical isomer, a polymorph, an isotope derivative or a pharmaceu...  
WO/2024/098735A1
The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, and an organic electroluminescent apparatus and an electronic device using same. The organic compound has a struct...  
WO/2024/099402A1
Provided are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and us...  
WO/2024/099908A1
The invention relates to compounds of formula Iwherein R1, R2, R3, R4, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such a...  
WO/2024/102810A1
The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific pro...  
WO/2024/099907A1
The invention relates to compounds of formula I wherein R1, R2, R3, A, D, E, G, J, K and L are defined as in claim 1, and prodrugs, deuterated analogues and pharmaceutical acceptable salts thereof, for the treatment of diseases such as s...  
WO/2024/099400A1
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparatio...  
WO/2024/099395A1
Disclosed herein are novel bifunctional compounds of formula (I) formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and method...  
WO/2024/097296A1
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...  
WO/2024/094171A1
A substituted aminopyrimidine compound, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, in particular as an EGFR inhibitor and/or degradation agent and the us...  
WO/2024/097172A1
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...  
WO/2024/095012A1
The invention relates to a compound of formula (Ia) and related aspects.  
WO/2024/097606A1
The present disclosure relates to certain AHR agonist compounds, for example, having a general formula (I) to pharmaceutical compositions comprising the compounds, and to methods of using the compounds to treat immune-mediated diseases, ...  
WO/2024/088189A1
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.  
WO/2024/091894A1
The present disclosure is directed to novel PNU Anthracycline Derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the above disclosure. The disclosure is also directed to pharmac...  
WO/2024/088307A1
Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...  
WO/2024/088110A1
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...  
WO/2024/090469A1
The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of th...  
WO/2024/089683A1
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.  
WO/2024/082645A1
The present application relates to the technical field of organic electroluminescence, and relates to an organic compound, an organic electroluminescent device using same, and an electronic device. The organic compound has a structure as...  
WO/2024/083980A1
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...  
WO/2024/086296A1
The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...  
WO/2024/084390A1
Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or periphe...  
WO/2024/085661A1
Provided are triheterocyclic compounds, and more specifically triheterocyclic compounds useful as KRAS protein inhibitors, and a pharmaceutical composition including the same for treating cancers.  
WO/2024/086634A1
The application relates to heterocyclic heteroaromatic macrocyclic ether compounds of the general Formula (I), pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds act as selective inh...  
WO/2024/083223A1
The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...  
WO/2024/085036A1
A compound represented by formula (1) (the symbols in formula (1) are as defined in the description); an organic electroluminescent element containing the compound; and an electronic appliance containing the organic electroluminescent el...  
WO/2024/083146A1
The present invention relates to a compound of general formula (A) and a pharmaceutical composition thereof. The compound of formula (A) provided in the present invention can be used for preventing and/or treating diseases related to the...  
WO/2024/083168A1
Provided herein are oxazepinyl compounds comprising a 6-aza moiety that are useful in the treatment of cancers.  
WO/2024/083933A1
There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I), (I) and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are modulator...  
WO/2024/078263A1
The present invention relates to a macrocyclic heterocyclic compound as a selective inhibitor of a clinical mutant of EGFR kinase, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt ther...  
WO/2024/078372A1
Provided are a heterocyclic substituted phenol derivative, a preparation method therefor, and a use thereof. Specifically, provided are compounds of formulas (I-1), (II-1B), (III), and (IV), stereoisomers thereof, pharmaceutically accept...  
WO/2024/079128A1
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example,  Z is representing a (II)  X is representing a NR5R6 group wherein R5 and R6 are hydrogen,  R1 is represe...  
WO/2024/081927A1
Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...  
WO/2024/078620A1
A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical comp...  
WO/2024/074080A1
Disclosed in the present invention are a highly effective antiviral derivative and a use thereof. The derivative is a compound shown in formula (I-0) or a hydrate, solvate, optical isomer, polymorphic substance, isotope derivative, or ph...  
WO/2024/074611A1
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...  
WO/2024/075815A1
The present invention addresses the problem of providing a cMLCK activator which can enhance myocardial contraction without the need to increase the concentration of calcium in cells. The problem is solved by a cMLCK activator comprising...  
WO/2024/075696A1
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...  
WO/2024/076693A1
Disclosed herein are compounds of Formula I and methods for using the same for treating or preventing an infection caused by a mycobacterium in a subject in need thereof. The method comprises administering to the subject the compound of ...  

Matches 1 - 50 out of 12,086